Industry Meetings
News:

July 14, 2008
Nephros Exhibiting at Maryland ASHE Conference
July 20-23, 2008
Click here for additional information

June 5, 2008
Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
Click here for additional information

June 2, 2008
Nephros exhibiting at Denver, Colorado APIC Conference
June 15-19, 2008

Click here for additional information

May 10, 2008
Nephros to Exhibit at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008
Click here for additional information

October 16, 2007
Nephros Initiates Pivotal U.S. Trial for OLpur™ H2H™
Hemodiafiltration Module and OLpur™ MD 220 Hemodiafilter
Click here for additional information

October 3, 2007
Nephros Receives Non-Compliance Notification from Amex
Click here for additional information

September 25, 2007
Nephros Raises $12.7 Million in New Financing
Click here for additional information

August 13, 2007
Nephros Reports Second Quarter 2007 Financial Results
Revenues Increase 15%, Net Loss is Reduced
Click here for additional information

August 7, 2007
Nephros Discloses Nonpayment of Installment under the Lancer
Settlement Agreement in Current Report on Form 8-K
Click here for additional information

July 20, 2007
Nephros Names New Independent Auditing Firm
Click here for additional information

May 23, 2007
Nephros Reports Departure of Director
Click here for additional information

May 16, 2007
Nephros to Initiate U.S. Clinical Trials
Click here for additional information

May 15, 2007
Nephros Reports First Quarter 2007 Financial Results
Revenues Increase 70%, Net Loss is Reduced
Click here for additional information

May 3, 2007
Nephros Provides Information Regarding Auditor's Going Concern
Report and Fiscal 2006 Results
Click here
for additional information

May 1, 2007
Nephros Reports Departure of Director
Click here for additional information

March 1, 2007
Nephros Completes Informational Request from the FDA
on Investigational Device Exemption Application

Nephros MD and H2H Technologies Clinical Trials Expected to Commence in March 2007
Click here for additional information

January 29, 2007
Nephros Receives Conditional Approval from the FDA
of Investigational Device Exemption Application

Nephros MD and H2H Technologies Targeted to Begin Clinical Trials
in First Quarter 2007
Click here for additional information
Nephros can be found on the American Stock Exchange under
the ticker symbol NEP. Click here for additional information.
 

Dialysis Industry meetings:

  • Nov 4 - Nov 9, 2008
    American Society of Nephrology ASN
    Philadelphia, PA

Water Industry Meetings:

  • Oct 22 - 25, 2008
    American Society of Healthcare Risk Management
    Denver, CO

  • Jul 20 - Jul 23, 2008
    American Society of Healthcare Engineering (ASHE) of the American Hospital Association (AHA)
    Washington, DC / Booth #839

  • Jun 15 - Jun 19, 2008
    APIC 2008
    Denver, CO

The Future of ESRD Therapy
Nephros, Inc. has developed new system technologies and companion products that will improve survival, increase the quality of life, and reduce medical costs for patients with End Stage Renal Disease (ESRD). The Company has developed unique and proprietary technologies that address the major overriding needs of ESRD treatment by providing:

Significant improvement in treatment efficacy, particularly with respect to the removal of many harmful substances, such as the "middle molecule" beta-2-microglobulin, not effectively removed by current dialytic methods.

Cost effective therapies that provide a better life for the patient while meeting the business needs of the clinic.

© 2007 Nephros, Inc.